Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: A case report

Keyphrases

• Aripiprazole 100%
• Pharmacogenetics 100%
• Psychosis 100%
• Aripiprazole Long-acting Injection 100%
• Long-acting Injectable 80%
• Dopamine D2 Receptor (DRD2) 60%
• Antipsychotics 40%
• High Dose 40%
• Wearing-off 40%
• Pharmacogenetic Testing 40%
• Dosing Strategy 40%
• Psychiatric Hospital 40%
• Aripiprazole Lauroxil 40%
• Pharmacokinetics 20%
• African American Men 20%
• Genotype 20%
• Genetic Influences 20%
• Medication Management 20%
• Pharmacokinetic Profile 20%
• Clinical Utility 20%
• Genetic Factors 20%
• Patient Symptoms 20%
• Response to Therapy 20%
• Metabolic Pathway 20%
• Two-agent 20%
• Dose Requirement 20%
• Symptom Improvement 20%
• Daily Dose 20%
• Clinical Test 20%
• Re-emergence 20%
• Poor Response 20%
• Drug Metabolism 20%
• Medication Regimen 20%
• Response to Antipsychotics 20%
• Schizoaffective Disorder 20%
• Symptom Presentation 20%
• Normal Activity 20%
• Older African Americans 20%
• DRD2 Gene 20%
• Dose Equivalent 20%
• Long-acting Injectable Antipsychotics 20%
• Unique Response 20%

Medicine and Dentistry

• Pharmacogenetics 100%
• Aripiprazole 100%
• Typical Antipsychotic 50%
• Drug Therapy 33%
• Drug Megadose 33%
• Pharmacokinetics 33%
• Mental Hospital 33%
• Pharmacogenetic Testing 33%
• Aripiprazole Lauroxil 33%
• Receptor 16%
• Heredity 16%
• Equivalent Dose 16%
• Schizoaffective Disorder 16%
• Case Presentation 16%
• Dopamine Receptor D2 16%
• Drug Metabolism 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Aripiprazole 100%
• Pharmacogenetics 100%
• Typical Antipsychotic 50%
• Aripiprazole Lauroxil 33%
• Pharmacokinetics 33%
• Antipsychotic 16%
• Receptor 16%
• Schizoaffective Psychosis 16%
• Dopamine Receptor D2 16%
• Drug Metabolism 16%